CD5-positive marginal zone lymphoma: Clinicopathological features and survival outcomes
Yaqin Xia(First Affiliated Hospital of Zhengzhou University), Xiaorui Fu(First Affiliated Hospital of Zhengzhou University), Mingzhi Zhang(Chinese Academy of Sciences), Feifei Nan(First Affiliated Hospital of Zhengzhou University), Jurui Ge(First Affiliated Hospital of Zhengzhou University), Wenjuan Wan(The Affiliated Yongchuan Hospital of Chongqing Medical University), Zhenchang Sun(First Affiliated Hospital of Zhengzhou University), Duo Xu(University of Wisconsin–Madison)
Cited by 10
Related Papers
PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?
|Frontiers in Immunology|2017|296
Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor
|Journal of Hematology & Oncology|2016|250
miR-137 Is Frequently Down-Regulated in Gastric Cancer and Is a Negative Regulator of Cdc42
|Digestive Diseases and Sciences|2011|140
miR-153 suppresses IDO1 expression and enhances CAR T cell immunotherapy
|Journal of Hematology & Oncology|2018|134